entertainment -WSS

entertainment

author：leisure time 2025-09-30 00:09:56 - browse：4

An Ozempic pen connects dots that make up the shape o a brain — coverage from STAT — ILLUSTRATION: CHRISTINE KAO/STAT; PHOTOS: ADOBE

Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are being studied to treat an entirely different growing health problem: mental health illnesses, including depression and bipolar disorder.

Early data and anecdotes suggest that this class of GLP-1 drugs could help patients feel less depressed and anxious. The treatment may also fight the decline in cognitive and executive function that many people with mental health disorders experience, like worsening memory and losing the ability to focus and plan.

If further research yields positive results, it could drive even more demand for the highly popular GLP-1 treatments, which have increasingly been shown to help with problems across the body, such as heart and kidney complications. And especially if the cognitive benefits are proven out, the GLP-1 drugs would plug a critical gap in current treatments for depression, since most depression drugs help with mood, but close to none address cognitive symptoms that affect memory and attention.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout Newsletter: CAR

Wikipedia

WSS

How many hemophilia patients actually want gene therapy?

Change Healthcare outage fallout shows need for new oversight

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Steward Health Care Massachusetts hospitals face fiscal disaster

Why depression after traumatic brain injury is distinct

Change Healthcare outage fallout shows need for new oversight

hotspot

entertainment

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

United colonoscopy coverage change 'may cost lives,' doctors say

Change Healthcare outage fallout shows need for new oversight

ChatGPT in medicine: STAT answers readers' burning questions

Decaf coffee targeted by food safety group under obscure FDA rule

Virginia high school admissions case could be legal follow

Readout Newsletter: Merck, Vertex, and Viking updates

FDA approval of Sarepta Duchenne genetic therapy gives me hope

WuXi out of biotech trade group, U.S. and China relations to blame

knowledge

Abortion pill case raises question: who can sue the FDA?

Steward Health Care has deal to sell doctor network to UnitedHealth

Merck drug for rare lung condition set for approval in U.S.

The Readout: Lenmeldy, GLP

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

First U.S. drug developed to treat liver disease MASH is approved

leisure time

entertainment

Wikipedia

hotspot